Literature DB >> 15152603

One-week 96-well soft agar growth assay for cancer target validation.

Ning Ke1, Aaron Albers, Gisela Claassen, De-hua Yu, Jon E Chatterton, Xiuyuan Hu, Bernd Meyhack, Flossie Wong-Staal, Qi-Xiang Li.   

Abstract

Soft agar growth, used to measure cell anchorage-independent proliferation potential, is one of the most important and most commonly used assays to detect cell transformation. However, the traditional soft agar assay is time-consuming, labor-intensive, and plagued with inconsistencies due to individual subjectivity. It does not, therefore, meet the increasing demands of today's oncology drug target screening or validation processes. This report describes an alternative 96-well soft agar growth assay that can function as a replacement for the traditional method and overcomes the aforementioned limitations. It offers the following advantages: a shortened assay duration (1 week instead of 4 weeks) that makes transient transfection or treatment possible; plate reader quantification of soft agar growth (measuring cloning efficiency and colony size); and a significant reduction in required labor. Higher throughput also makes it possible to process large numbers of samples and treatments simultaneously and in a much more efficient manner, while saving precious workspace and overall cost.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15152603     DOI: 10.2144/04365ST07

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  22 in total

1.  MDDD, a 4,9-diazapyrenium derivative, is selectively toxic to glioma cells by inducing growth arrest at G0/G1 independently of p53.

Authors:  De-Hua Yu; James Macdonald; Steve Josephs; Qi Liu; Vivian Nguy; Yitzhak Tor; Flossie Wong-Staal; Qi-Xiang Li
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

2.  Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.

Authors:  Aishwarya G Jacob; Dennis O'Brien; Ravi K Singh; Daniel F Comiskey; Robert M Littleton; Fuad Mohammad; Jordan T Gladman; Maria C Widmann; Selvi C Jeyaraj; Cheryl Bolinger; James R Anderson; Donald A Barkauskas; Kathleen Boris-Lawrie; Dawn S Chandler
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

3.  HBZ-mediated shift of JunD from growth suppressor to tumor promoter in leukemic cells by inhibition of ribosomal protein S25 expression.

Authors:  M Terol; H Gazon; I Lemasson; M Duc-Dodon; B Barbeau; R Césaire; J-M Mesnard; J-M Péloponèse
Journal:  Leukemia       Date:  2017-03-06       Impact factor: 11.528

4.  An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.

Authors:  Martin Indarte; Roisin Puentes; Marco Maruggi; Nathan T Ihle; Geoffrey Grandjean; Michael Scott; Zamal Ahmed; Emmanuelle J Meuillet; Shuxing Zang; Robert Lemos; Lei Du-Cuny; Fabiana I A L Layng; Ricardo G Correa; Laurie A Bankston; Robert C Liddington; Lynn Kirkpatrick; Garth Powis
Journal:  Cancer Res       Date:  2019-04-30       Impact factor: 12.701

5.  The Cancer BioChip System: a functional genomic assay for anchorage-independent three-dimensional breast cancer cell growth.

Authors:  Rula A Abbud-Antaki; Joie N Marhefka; Aimee L DeLuca; Michael P Zuromskis
Journal:  Horm Cancer       Date:  2012-06-12       Impact factor: 3.869

6.  Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.

Authors:  Q K Y Chan; H-M Lam; C-F Ng; A Y Y Lee; E S Y Chan; H-K Ng; S-M Ho; K-M Lau
Journal:  Cell Death Differ       Date:  2010-03-05       Impact factor: 15.828

7.  Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation.

Authors:  Seung-Shick Shin; Jin Namkoong; Brian A Wall; Ryan Gleason; Hwa Jin Lee; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-04-23       Impact factor: 4.693

8.  Establishment and characterization of a new feline mammary cancer cell line, FkMTp.

Authors:  Ana Borges; Filomena Adega; Raquel Chaves
Journal:  Cytotechnology       Date:  2016-02-17       Impact factor: 2.058

9.  TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells.

Authors:  Chris Brunquell; Hector Biliran; Scott Jennings; Shubha Kale Ireland; Renwei Chen; Erkki Ruoslahti
Journal:  Mol Cancer Res       Date:  2012-09-04       Impact factor: 5.852

10.  Establishment and characterisation of a novel bovine SV40 large T-antigen-transduced foetal hepatocyte-derived cell line.

Authors:  Alexander Gleich; Bastian Kaiser; Julia Schumann; Herbert Fuhrmann
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-04-12       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.